Targeting immune cells in vaccination

AbVision announces first-in-class active targeting vaccine candidate for COVID-19
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MILPITAS, Calif.—Biopharmaceutical company AbVision Inc. announced May 1 that the company has developed a first-in-class COVID-19 vaccine (AVI-205) with an active targeting feature, powered by its patented ImmunoBuster-IITM Active Targeting Vaccine Platform.
 
This novel COVID-19 vaccine actively targets immune cells upon injection as compared to the passive diffusion mechanism of traditional vaccines, according to AbVision, generating strong SARS-CoV-2 S1-hACE2 neutralizing immune response in less than a week as compared to a two weeks similar response from traditional vaccines.
 
The company has now successfully completed preclinical studies and generated what is says are promising data. As a result, this novel COVID-19 vaccine candidate is now available for out-licensing and collaborations for downstream development and clinical studies, according to AbVision.
 
The company’s ImmunoBuster-II Active Targeting Vaccine Platform is, as described by AbVision, “a first-in-class potent immune activator with targeting feature, created on top of the innovation of the Company’s renowned ImmunoBuster-ITM technology. Vaccines powered by ImmunoBuster-IITM can elicit robust isotype switched IgG response in less than a week and maintain long-lasting IgG response for more than three weeks post vaccination.”
 
Reportedly, ImmunoBuster-IITM can work synergistically with essentially all commercially available vaccines to elicit faster and stronger neutralizing immunity than current vaccinations.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue